Horticultural Milestones of Berry Pharmaceuticals, LLC
2011-2013
Texas A&M University was commissioned in a Sponsored Research Agreement (SRA) between Texas A&M University Horticultural Science Department and Berry Pharmaceuticals, LLC to develop optimal commercialization protocol in Horticulture Science in growing, propagation, cultivation, harvesting, and all facets related to a specific clone of a rainforest plant. The results of this 24-month study have been incorporated into Intellectual Property in a monograph report (proprietary trade secret document) belonging to Berry Pharmaceuticals, LLC. The plant now has an A&M historical pedigree.
2013-2014
Pilot study in private greenhouse growing was performed to verify and certify all that A&M stated in the protocols.
2014-2015
Full capacity private greenhouse production of 12,000 plants was examined in depth. The final botanical biomass was standardized, triple packaged and secured with a shelf life. This biomass was then used to create botanical extracts for definitive use in making selected cosmeceutical prototype products.
2015-2018
After 4 1/2 years of R&D in horticulture science study, Berry was capable of generating exquisitely refined botanical extracts such as Cupió-Rase used in the production of cosmeceutical anti-aging skin care product line.
2016-2019
Prototype botanical extracts were developed for our first two pharmaceutical prototypes. The Radiation Dermatitis patent was issued in 2016 and the Major Thermal Burn was issued in 2019.
2020-2022
Final discovery prototype was formulated. New construction of pharmaceutical grade biomedical greenhouse began in 2020 and became fully operational.
2022-2023
The first two new drugs are soon to begin the FDA Botanical Guidance Pathway in order to become FDA approved new pharmaceutical drugs for Radiation Dermatitis and Major Thermal Burn, depending on funding.
